Enovis (NYSE:ENOV) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Enovis (NYSE:ENOV) from a hold rating to a buy rating in a research report report published on Monday morning,Wall Street Zen reports.

A number of other equities analysts also recently commented on ENOV. Citizens Jmp reduced their price objective on shares of Enovis from $55.00 to $47.00 and set a “market outperform” rating for the company in a research note on Wednesday, September 2nd. BTIG Research lowered their price target on shares of Enovis from $40.00 to $36.00 and set a “buy” rating on the stock in a report on Tuesday, September 1st. Wells Fargo & Company cut their price objective on shares of Enovis from $39.00 to $33.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 2nd. BMO Capital Markets set a $27.00 price objective on shares of Enovis in a research note on Tuesday, September 1st. Finally, Citigroup reissued a “market outperform” rating on shares of Enovis in a research report on Wednesday, September 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $40.38.

Enovis Price Performance

ENOV opened at $18.30 on Monday. Enovis has a 12-month low of $17.30 and a 12-month high of $34.28. The business’s fifty day simple moving average is $23.23 and its 200-day simple moving average is $23.53. The company has a market capitalization of $1.06 billion, a price-to-earnings ratio of -0.95 and a beta of 1.31. The company has a current ratio of 1.98, a quick ratio of 1.00 and a debt-to-equity ratio of 0.84.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.85 by $0.05. Enovis had a negative net margin of 47.96% and a positive return on equity of 12.03%. The company had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same period in the prior year, the business earned $0.79 EPS. The firm’s quarterly revenue was up 3.2% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts anticipate that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Transactions at Enovis

In other news, insider Oliver Engert acquired 2,660 shares of Enovis stock in a transaction that occurred on Friday, September 4th. The stock was purchased at an average cost of $18.80 per share, with a total value of $50,008.00. Following the purchase, the insider owned 63,898 shares in the company, valued at $1,201,282.40. This trade represents a 4.34% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Damien Mcdonald acquired 13,035 shares of the firm’s stock in a transaction on Friday, September 4th. The stock was purchased at an average price of $19.15 per share, for a total transaction of $249,620.25. Following the acquisition, the chief executive officer directly owned 247,077 shares in the company, valued at $4,731,524.55. This represents a 5.57% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought 23,293 shares of company stock valued at $449,599 in the last three months. Corporate insiders own 2.90% of the company’s stock.

Institutional Investors Weigh In On Enovis

A number of large investors have recently modified their holdings of the business. IFP Advisors Inc grew its stake in Enovis by 5,590.5% during the 2nd quarter. IFP Advisors Inc now owns 1,195 shares of the company’s stock valued at $25,000 after acquiring an additional 1,174 shares in the last quarter. Allworth Financial LP purchased a new position in Enovis in the 2nd quarter worth approximately $36,000. Integrated Wealth Concepts LLC acquired a new position in shares of Enovis during the 2nd quarter worth approximately $39,000. Public Employees Retirement System of Ohio acquired a new position in shares of Enovis during the 2nd quarter worth approximately $48,000. Finally, Annis Gardner Whiting Capital Advisors LLC grew its position in shares of Enovis by 468,400.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 4,685 shares of the company’s stock valued at $107,000 after purchasing an additional 4,684 shares in the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis Corporation is a medical technology company that develops, manufactures and distributes products designed to improve patient mobility, support recovery and restore physical function. Its offerings serve orthopedic, sports medicine, rehabilitation and pain-management markets, with products used by healthcare professionals, athletes and patients.

The company’s product portfolio includes orthopedic braces and supports, surgical solutions, cold and compression therapy systems, rehabilitation equipment, physical therapy devices and recovery technologies.